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How to Supplement Endpoints
of Ventricular Tachycardia
Ablation
Is There a Role for Noninvasive
Programmed Ventricular Stimulation?*
Gerhard Hindricks, MD, Christopher Piorkowski, MD
Leipzig, Germany
Endpoints for interventional procedures such as catheter
ablation should be clearly defined, reproducible, practicable
to measure, and widely accepted. In addition, good end-
points should have significant predictive impact on long-
term outcome (e.g., the recurrence of tachycardia after
successful catheter ablation procedures). By that, they are
not only markers of treatment quality for the individual
patient but also of utmost scientific value because they allow
the solid comparison of different treatment technologies or
treatment strategies. In the field of catheter ablation, we
have the privilege of having such endpoints for most of the
procedures being performed: complete accessory pathway
block in patients with Wolff-Parkinson-White syndrome
syndrome or bidirectional isthmus block in patients with
typical atrial flutter predict a very low risk for arrhythmia
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recurrence during long-term follow-up. Even in patients
with complex arrhythmias such as paroxysmal atrial fibril-
lation, the endpoint of complete pulmonary vein isolation is
well defined and generally accepted. In the setting of
catheter ablation of ventricular tachycardia (VT) in patients
with organic heart disease, however, procedural endpoints
are less well defined. The most widely accepted endpoint is
noninducibility of VT by programmed ventricular stimula-
tion assessed at the end of the ablation procedure (1,2).
Definition of noninducibility may relate to the clinical
tachycardia, to VT of certain cycle lengths (e.g., only those
with a cycle length equal to or longer than the clinical
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no standards for the stimulation protocol pre-ablation and
post-ablation (e.g., number of extrastimuli applied, basic
drive cycle length, number of stimulation sites) are generally
accepted. In addition, execution of endpoint assessment by
using programmed stimulation at the end of an ablation
procedure is sometimes limited by the unstable medical
conditions of the patients being treated. Moreover, comple-
tion of a full programmed stimulation protocol after hours
of VT ablation may require some discipline, which at times
is difficult to deliver.
The best conditions to apply programmed stimulation are
found in patients with remote myocardial infarction and the
following: 1) 12-lead electrocardiogram documentation of
the clinical tachycardia; 2) reproducible inducibility of the
clinical tachycardia; and 3) no inducibility of other nonclini-
cal tachycardias. Delineation of areas critical for the main-
tenance of the tachycardia by means of voltage- and pace-
mapping and/or activation- and entrainment-mapping
often allows the creation and delivery of an effective ablation
strategy, which terminates the tachycardia and renders the
patient noninducible. However, in clinical practice, this
situation is rare. Frequently, ablation sessions are compli-
cated by the inducibility of multiple VT morphologies
and/or fast and hemodynamic instable tachycardias requir-
ing repetitive electrical defibrillation (1,2). In addition,
precise identification of a clinical tachycardia may be diffi-
cult in patients without 12-lead electrocardiogram docu-
mentation. In the setting of incessant VT or electrical
storm, it is also almost impossible to assess the complete
preablation inducibility due to the critical clinical situation.
During the ablation session, factors such as sedation or
general anesthesia, other pharmacological interventions,
changes in autonomic tone, transient ischemia, or hemody-
namic deterioration may also have an influence on the
reproducibility of tachycardia induction. With these limita-
tions in mind, what is the value and relevance of pro-
grammed stimulation as an endpoint for the procedure and
as a useful tool for risk assessment for VT recurrence?
Early single-center studies in patients with post-
myocardial VT undergoing catheter ablation indicated some
value of programmed stimulation to predict the risk for
tachycardia recurrence during mid-term follow-up (3–5).
These studies found that patients rendered completely
noninducible by the ablation procedure were at significantly
lower risk for the recurrence of clinical and nonclinical VT
during follow-up. However, even the noninducible patients
still had a considerable risk of VT recurrence of approxi-
mately 20% to 30% during the first year after ablation. In
most of the more recent larger-scale, single-center and
multicenter studies, no significant predictive value of pro-
grammed stimulation performed at the end of the ablation
procedure was observed for VT recurrence during follow-up
(6–9). In these studies, other markers were identified to
predict VT recurrence such as number of inducible tachy-
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eter, presence of incessant VT, or advanced heart failure.
These divergent results may be in part due to the changes in
patient population undergoing catheter ablation more than
10 years ago compared with more recent studies. Indeed, the
widespread use of thrombolysis and/or immediate coronary
intervention, which have become standard for the treatment
of acute myocardial infarction, have changed the substrate
of VT and the response to programmed stimulation (10).
In this issue of the Journal, Frankel et al. (11) report the
results of an interesting study in which programmed ven-
tricular stimulation was performed noninvasively days after
a VT ablation procedure via implanted implantable
cardioverter-defibrillator devices (noninvasive programmed
ventricular stimulation [NIPS]) in addition to acute postab-
lation stimulation to improve prediction of VT recurrence.
More than two-thirds of the patients investigated had
ischemic VT and approximately one-third had nonischemic
VT. Only 11 of 167 patients who underwent direct postab-
lation programmed stimulation had inducible clinical VT
(7%). These patients did not undergo NIPS, unfortunately;
it would have been interesting to see reproducibility of
clinical VT induction at NIPS. After excluding an addi-
tional 46 patients (mainly for clinical reasons) and 11
patients with spontaneous recurrence of clinical VT, a total
of 132 patients finally underwent NIPS approximately 3
days after the ablation procedure. Twenty-four of 132
patients had inducible clinical VT (18%), 49 patients had
inducible nonclinical VT (37%), and 59 patients (45%) were
not inducible. The main finding of the study is that a
relatively high percentage of patients being noninducible at
the end of the ablation session have inducible clinical VT
just a few days after the procedure. This finding may be
explained by the lack of durability of radiofrequency-
induced ventricular lesions potentially allowing re-
conduction through critical VT isthmus sites effectively
blocked during the ablation session.
The results of the study by Frankel et al. (11) provide
additional evidence that re-conduction may play a signifi-
cant role for the recurrence of VT, similar to what has been
shown in patients undergoing catheter ablation for atrial
fibrillation. In addition, the cofactors for the limited pre-
dictive strength of programmed stimulation at the end of
the ablation session defined here (e.g., general anesthesia,
pharmacological intervention) may have at least in part been
overcome by performing programmed stimulation at a later
stage. Although not powered as a mortality study, it is
striking to recognize the high 1-year mortality rates ob-
served in patients with inducible clinical VT (21%) and
inducible nonclinical VT (23%) at NIPS versus only 3% in
noninducible patients. However, the details on the mode of
death in these patients were not reported. Sadly, according
to Figure 2 of the paper (11) and unfortunately not
explained by the authors in detail, the recurrence rate of any
VT in NIPS-negative patients at 400 days of follow-up still
was close to 20%.The most striking limitation of NIPS is that this strategy
is not very helpful as an endpoint for catheter ablation of
VT. The procedure occurred days before re-assessment and
potential validation of the intervention outcome. What to
do with “NIPS-positive” patients? Possibilities include early
re-ablation, intense and careful follow-up, or addition of
antiarrhythmic drugs. Nevertheless, progress to improve
outcome of patients with recurrent VT undergoing catheter
ablation slowly evolves, and the important new data pro-
vided by the study from Frankel et al. (11) represent such a
step. However, additional studies are clearly necessary to
further delineate the role of NIPS to better understand the
prediction of VT recurrence after catheter ablation and to
improve the management and outcome of such patients. As
a word of caution: in the past, programmed stimulation has
failed many times to predict efficacy of antiarrhythmic
drugs, to identify candidates for implantable cardioverter-
defibrillator implantation, and to identify patients with high
risk for sudden cardiac death (12). Hopefully, history will
not repeat with NIPS.
Are there alternatives on the horizon for endpoints better
than those generated by programmed stimulation for the
prediction of risk for recurrence of VT after catheter
ablation? Nothing that is clearly visible at this point in time.
New treatment strategies such as combined endo- and
epicardial ablation or the (complete?) ablation of late ven-
tricular activation (so-called LAVA ablation) are currently
under intense clinical investigation. Whether these aggres-
sive ablation strategies lead to overtreatment or improve the
outcome of patients undergoing catheter ablation of VT in
the presence of structural heart disease needs to be shown in
the studies to come. As long as we do not have convincing
studies presenting better endpoints, we should continue
to use noninducibility as the endpoint of VT catheter
ablation—potentially supported by NIPS.
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